Fungal pathogens pose serious medical, economic and ecological challenges. For instance, fungal infections of humans have a high death toll, which is similar to that of tuberculosis and higher than malaria. In particular, the Asian continent has an disproportionately high incidence of fungal infections. The number of therapeutic options for fungal infections is insufficient and the problem is complicated by the high incidence of antifungal drug resistance. Thus, the discovery of mechanisms of action of novel chemical entities may guide the adoption of new therapeutic schemes. In line with this goal, a valid strategy is to understand how regulated cell death can be induced and modulated in fungi. Staurosporine is a natural product previously shown by us to function as a potent fungal cell death inducer with antifungal properties. However, staurosporine lacks target selectivity, precluding its utilization in clinical contexts. To overcome this obstacle, we propose to synthesize new staurosporine derivatives from the family of indolocarbazole alkaloids and test their efficacy against the model fungus Neurospora crassa and a panel of fungal pathogens with clinical relevance. Our investigations could not only help to clarify the mechanism of action of indolocarbazoles, which have been demonstrated to have antiviral, antiparasitic and anticancer properties, but also lead to the identification of novel antifungal compounds. This research could serve as a very important contribution to the field of antifungal therapies. Overall, this project not only tackles a problem of high public interest but could also function as a steppingstone for a more substantial research effort in the future.